MYD88 and ovarian cancer: PTX could induce NF-κB and cJUN activation to promote IL-6, IL-8, VEGF and MCP-1 productions via a TLR4/MyD88-dependent pathway and resisted drug-induced apoptosis in ovarian cancer [9, 11].